Nevro wants to be more than just a spinal cord stimulation (SCS) company.
Since its founding about 17 years ago, the Redwood City, CA-based company has focused on developing and marketing its high-frequency 10 kHz (HFX) implantable SCS devices to treat chronic pain, including painful diabetic neuropathy and non-surgical refractory back pain
Nevro Acqures Vyrsa For Up To $75m
On 30 November, Nevro announced that it has signed and closed a deal to pay $40m at closing to acquire Pennsylvania-based Vyrsa.
Nevro also agreed to pay up to $35m in cash or stock based on the achievement of certain sales and development milestones. (Also see "News We’re Watching: New AF Guidelines, Nevro Buys Vyrsa, LivaNova Responds To Cyberattack" - Medtech Insight, 5 December, 2023.)
Vyrsa claims to be the only company to offer a complete line of state-of-the-art SI joint fusion devices cleared by the US Food and Drug Administration